Sabrina Martucci Johnson: Oh thanks for asking that. Now this is one where we did a lot of work with Bayer in the design of the study. And as you know, contraceptive trials on the one hand, it’s very cut and dry. I mean you’re looking at whether or not someone gets pregnant. But because Ovaprene is such an innovative, disruptive technology, there are a number of things that we and Bayer aligned on that we would also be collecting in this study in terms of just the pain for experience with the product. So questions really around things that are captured on electron diary around her experience with the product, her use of the product so that we have those insights. And then additionally, because it’s a once-a-month product. Again, similarly, there are aspects of that that we’re hoping to collect in the data from the trial, again, kind of related to that experience perspective as well as safety.
There are a number of safety endpoints in the study as well to really demonstrate kind of the convenience and safety of using a product of this nature. So when we ultimately do report the findings, it will be very much, as I alluded to in my comments, absolutely, it’s about efficacy. But we have also worked very closely with Bayer to make sure in this study that we’re collecting a lot of really useful, right? And to John’s point, about commercialization, useful data around usability and the patients – and sort of her experience with the product.
Doug Tsao: Okay. Great. Thank you so much.
Sabrina Martucci Johnson: Yes.
Operator: We have no further questions at this time. I’ll turn it back to Ms. Johnson for any closing remarks.
Sabrina Martucci Johnson: Great. Well, thank you. Thanks, everyone, for taking the time this afternoon. I know it’s a busy time of year, earnings season. So I appreciate you dialing in to hear about our recent updates, and our ongoing commitment to drive value for all of Daré’s stakeholders by addressing unmet needs in women’s health. And as you heard today, we are prioritizing women’s health and well-being by working to expand treatment options where none exists, or improve the current standard of care to address persistent unmet needs. We’re working closely with our collaborators, including the leading players we talked about today in women’s health, Organon and Bayer to bring these treatments to women around the world who need them. And ultimately, we believe we are uniquely positioned to improve quality of life for millions of women of women. We look forward to keeping you updated on our progress towards the milestones we discussed today. Thank you so much.
Operator: Ladies and gentlemen, this concludes today’s conference call. Thank you for participating. You may now disconnect.
